Health Canada’s chief medical adviser says the country is on track to approve Moderna’s COVID-19 vaccine soon–though Dr. Supriya Sharma provided no hard date.
Sharma told reporters Monday that Moderna provided the final clinical data on Friday to Health Canada, which has been reviewing the company’s vaccine since October.
All that’s left now, she said, is data on the manufacturing plants, which the department expects to receive by the end of the week.
“It does look promising and it does look positive,” Sharma said.
Canada, which already has enough vaccines secured to protect a population four times its size–the most of any country in the world–ordered an additional 20 million doses from Moderna earlier this month, bringing its confirmed order commitment to 40 million doses from the Massachusetts-based pharmaceutical giant.
Canada approved the Pfizer-BioNTech vaccine last week and what officials are calling the largest mass vaccination campaign in Canada’s history began yesterday when long-term care residents in Quebec City and Montreal and health-care workers in Toronto became the first persons in the country to receive their vaccinations
Vaccinations are scheduled today at a long-term facility in Ottawa and in Manitoba and Alberta tomorrow.
Procurement Minister Anita Anand said Monday she anticipates receiving 30,000 Pfizer-BioNTech doses both this week and next.
The federal government has said about 249,000 doses will arrive by the end of the month.
Both the Pfizer-BioNTech and the Moderna vaccines require two doses–21 days apart for Pfizer and 28 days apart for Moderna.
However, the Pfizer-BioNTech vaccine must be stored at temperatures below -70C while Moderna’s stays stable at -20C for up to six months.
That difference prompted Canada’s three northern territories–the Northwest Territories, Nunavut and Yukon–to wait for the Moderna vaccine.
Pfizer and Moderna together are expected to deliver 60 million doses of vaccine to Canada by next fall.
Sharma said Monday Health Canada was still reviewing AstraZeneca’s application after the company realized some patients in its clinical trial had not been given full doses of the vaccine.
She said Johnson & Johnson only submitted its application two weeks ago for Canadian approval and the teams are now conducting preliminary reviews.
Both the Pfizer-BioNTech and Moderna vaccines use messenger RNA technology, or mRNA, which directs cells in the body to make proteins to prevent or fight disease.
